[Pharmacogenetics in psychiatry: state of the art]

D J Müller; E J Brandl; F Degenhardt; K Domschke; H Grabe; O Gruber; J Hebebrand; W Maier; A Menke; M Riemenschneider; M Rietschel; D Rujescu; T G Schulze; L Tebartz van Elst; O Tüscher; J Deckert; das DGPPN Referat Neurobiologie und Genetik

doi:10.1007/s00115-017-0479-8

[Pharmacogenetics in psychiatry: state of the art]

Nervenarzt. 2018 Mar;89(3):290-299. doi: 10.1007/s00115-017-0479-8.

[Article in German]

Authors

D J Müller^{1

2}, E J Brandl^{3

4}, F Degenhardt⁵, K Domschke⁶, H Grabe⁷, O Gruber⁸, J Hebebrand⁹, W Maier¹⁰, A Menke¹¹, M Riemenschneider¹², M Rietschel¹³, D Rujescu¹⁴, T G Schulze¹⁵, L Tebartz van Elst⁶, O Tüscher¹⁶, J Deckert¹¹; das DGPPN Referat Neurobiologie und Genetik

Affiliations

¹ Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College St., R132, Toronto, ON, M5T 1R8, Kanada. [email protected].
² Department of Psychiatry, University of Toronto, Toronto, ON, Kanada. [email protected].
³ Klinik für Psychiatrie und Psychotherapie, Charité-Universitätsmedizin Berlin, Campus Mitte, Berlin, Deutschland.
⁴ Berlin Institute of Health, Berlin, Deutschland.
⁵ Institut für Humangenetik, Universitätsklinikum Bonn, Bonn, Deutschland.
⁶ Klinik für Psychiatrie und Psychotherapie, Universität Freiburg, Freiburg, Deutschland.
⁷ Klinik und Poliklinik für Psychiatrie und Psychotherapie an der Universitätsmedizin Greifswald, Universität Greifswald, Greifswald, Deutschland.
⁸ Klinik für Allgemeine Psychiatrie, Zentrum für Psychosoziale Medizin, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.
⁹ Klinik für Psychiatrie, Psychosomatik und Psychotherapie des Kindes- und Jugendalters, Universitätsklinikum Essen, Universität Duisburg-Essen, Essen, Deutschland.
¹⁰ Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Bonn, Bonn, Deutschland.
¹¹ Klinik und Poliklinik für Psychiatrie, Psychosomatik und Psychotherapie, Zentrum für Psychische Gesundheit, Universitätsklinikum Würzburg, Würzburg, Deutschland.
¹² Klinik für Psychiatrie, Universitätsklinikum des Saarlandes, Homburg/Saar, Deutschland.
¹³ Zentralinstitut für Seelische Gesundheit, Mannheim, Deutschland.
¹⁴ Klinik und Poliklinik für Psychiatrie, Psychotherapie und Psychosomatik, Martin-Luther-Universität Halle-Wittenberg, Halle, Deutschland.
¹⁵ Institut für Psychiatrische Phänomik und Genomik (IPPG), Klinikum der Universität München, LMU München, München, Deutschland.
¹⁶ Klinik für Psychiatrie und Psychotherapie, Universitätsmedizin der Johannes-Gutenberg Universität, Mainz, Deutschland.

PMID: 29383410
DOI: 10.1007/s00115-017-0479-8

Abstract

In this article, the current literature on pharmacogenetics of antidepressants, antipsychotics and lithium are summarized by the section of Neurobiology and Genetics of the German Society of Psychiatry, Psychotherapy and Neurology (DGPPN). The publications of international expert groups and regulatory authorities are reviewed and discussed. In Germany, a statement on pharmacogenetics was also made by the gene diagnostics committee of the Ministry of Health. The DGPPN supports two recommendations: 1) to perform CYP2D6 genetic testing prior to prescription of tricyclic antidepressants and 2) to determine the HLA-B*1502 genotype in patients of Asian origin before using carbamazepine. The main obstacle for a broad application of pharmacogenetic tests in psychiatry remains the lack of large prospective studies, for both single gene-drug pair and cobinatorial pharmacogenetic tests, to evaluate the benefits of genetic testing. Psychiatrists, geneticists and funding agencies are encouraged to increase their efforts for the future benefit of psychiatric patients.

Keywords: Antidepressants; Antipsychotics; Lithium; Personalised medicine; Pharmacokinetics.

Publication types

Review

MeSH terms

ATP Binding Cassette Transporter, Subfamily B / genetics
Antidepressive Agents / adverse effects
Antidepressive Agents / pharmacokinetics
Antidepressive Agents / therapeutic use*
Antidepressive Agents, Tricyclic / adverse effects
Antidepressive Agents, Tricyclic / pharmacokinetics
Antidepressive Agents, Tricyclic / therapeutic use
Antipsychotic Agents / adverse effects
Antipsychotic Agents / pharmacokinetics
Antipsychotic Agents / therapeutic use*
Asian People / genetics
Bipolar Disorder / drug therapy*
Bipolar Disorder / genetics
Carbamazepine / adverse effects
Carbamazepine / pharmacokinetics
Carbamazepine / therapeutic use
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2D6 / genetics
Depressive Disorder / drug therapy*
Depressive Disorder / genetics
Forecasting
Genetic Variation / genetics
Genotype
HLA-B15 Antigen / genetics
Humans
Lithium Compounds / adverse effects
Lithium Compounds / pharmacokinetics
Lithium Compounds / therapeutic use*
Pharmacogenetics / methods*
Pharmacogenetics / trends
Psychotic Disorders / drug therapy*
Psychotic Disorders / genetics

Substances

ABCB1 protein, human
ATP Binding Cassette Transporter, Subfamily B
Antidepressive Agents
Antidepressive Agents, Tricyclic
Antipsychotic Agents
HLA-B*15:02 antigen
HLA-B15 Antigen
Lithium Compounds
Carbamazepine
CYP2C19 protein, human
Cytochrome P-450 CYP2C19
Cytochrome P-450 CYP2D6